Several other research firms also recently weighed in on ZTS. Zacks Investment Research upgraded shares of Zoetis from a hold rating to a buy rating and set a $53.00 target price for the company in a report on Wednesday, June 15th. Citigroup Inc. raised their target price on shares of Zoetis from $50.00 to $53.00 and gave the company a neutral rating in a report on Thursday, August 4th. Barclays PLC raised their target price on shares of Zoetis from $45.00 to $49.00 and gave the company an equal weight rating in a report on Thursday, August 4th. Jefferies Group restated a buy rating and set a $60.00 target price on shares of Zoetis in a report on Tuesday, August 23rd. Finally, Credit Suisse Group AG restated a focus list rating and set a $60.00 target price on shares of Zoetis in a report on Wednesday, September 7th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $55.27.
Zoetis (NYSE:ZTS) opened at 51.42 on Wednesday. Zoetis has a 12-month low of $38.26 and a 12-month high of $53.14. The company has a market cap of $25.46 billion, a P/E ratio of 40.05 and a beta of 1.01. The firm’s 50 day moving average is $51.25 and its 200 day moving average is $48.94.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.05. The firm earned $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. Zoetis’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 EPS. Equities research analysts anticipate that Zoetis will post $1.91 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Thursday, November 3rd will be given a dividend of $0.095 per share. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a yield of 0.74%. Zoetis’s dividend payout ratio (DPR) is 29.69%.
In other news, insider Andrew Fenton sold 13,870 shares of the business’s stock in a transaction on Friday, September 2nd. The shares were sold at an average price of $51.25, for a total transaction of $710,837.50. Following the transaction, the insider now directly owns 17,719 shares of the company’s stock, valued at $908,098.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Heidi C. Chen sold 32,097 shares of the business’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the transaction, the insider now directly owns 46,060 shares in the company, valued at $2,348,138.80. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Gilder Gagnon Howe & Co. LLC boosted its position in Zoetis by 0.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 6,730 shares of the company’s stock worth $319,000 after buying an additional 26 shares during the last quarter. Sterneck Capital Management LLC boosted its position in Zoetis by 0.7% in the second quarter. Sterneck Capital Management LLC now owns 5,766 shares of the company’s stock worth $274,000 after buying an additional 38 shares during the last quarter. Kistler Tiffany Companies LLC boosted its position in Zoetis by 1.1% in the second quarter. Kistler Tiffany Companies LLC now owns 6,231 shares of the company’s stock worth $296,000 after buying an additional 65 shares during the last quarter. Fulton Bank N.A. boosted its position in Zoetis by 1.6% in the third quarter. Fulton Bank N.A. now owns 5,279 shares of the company’s stock worth $275,000 after buying an additional 83 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its position in Zoetis by 1.9% in the first quarter. Jones Financial Companies Lllp now owns 6,039 shares of the company’s stock worth $268,000 after buying an additional 114 shares during the last quarter. 93.12% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.